Purpose: Forming a patient safety culture is the first step in addressing patient safety issues. This study therefore examines the patient safety culture among healthcare professionals in South Korea. It also identifies the factors influencing patient safety culture and related activities. Methods: Among the survey studies conducted in South Korea, we reviewed those that measured patient safety culture using the Korean version of the Hospital Survey on Patient Safety Culture 1.0. We identified the level of patient safety culture, the relationship between patient safety culture and patient safety activities, and the factors affecting patient safety culture. Results: A total of 640 studies were identified through searches of seven domestic and international databases, with 58 included in the analysis. Studies targeting nurses accounted for 96.6%. The general characteristics of patient safety culture included length of service, age, working hours, department of work, hospital size, conflict occurrence, unreported incidents, and subjective safety management evaluations. A statistically significant correlation between patient safety culture and patient safety activities was confirmed in 84.5% of studies. Patient safety culture was the most frequently reported factor influencing patient safety activities. Conclusion Strategies to enhance patient safety culture can promote patient safety activities in South Korean healthcare institutions. Considering organizational and organizational members characteristics when devising these strategies can enhance their effectiveness.

Purpose: Forming a patient safety culture is the first step in addressing patient safety issues. This study therefore examines the patient safety culture among healthcare professionals in South Korea. It also identifies the factors influencing patient safety culture and related activities. Methods: Among the survey studies conducted in South Korea, we reviewed those that measured patient safety culture using the Korean version of the Hospital Survey on Patient Safety Culture 1.0. We identified the level of patient safety culture, the relationship between patient safety culture and patient safety activities, and the factors affecting patient safety culture. Results: A total of 640 studies were identified through searches of seven domestic and international databases, with 58 included in the analysis. Studies targeting nurses accounted for 96.6%. The general characteristics of patient safety culture included length of service, age, working hours, department of work, hospital size, conflict occurrence, unreported incidents, and subjective safety management evaluations. A statistically significant correlation between patient safety culture and patient safety activities was confirmed in 84.5% of studies. Patient safety culture was the most frequently reported factor influencing patient safety activities. Conclusion Strategies to enhance patient safety culture can promote patient safety activities in South Korean healthcare institutions. Considering organizational and organizational members characteristics when devising these strategies can enhance their effectiveness.

Purpose: Forming a patient safety culture is the first step in addressing patient safety issues. This study therefore examines the patient safety culture among healthcare professionals in South Korea. It also identifies the factors influencing patient safety culture and related activities. Methods: Among the survey studies conducted in South Korea, we reviewed those that measured patient safety culture using the Korean version of the Hospital Survey on Patient Safety Culture 1.0. We identified the level of patient safety culture, the relationship between patient safety culture and patient safety activities, and the factors affecting patient safety culture. Results: A total of 640 studies were identified through searches of seven domestic and international databases, with 58 included in the analysis. Studies targeting nurses accounted for 96.6%. The general characteristics of patient safety culture included length of service, age, working hours, department of work, hospital size, conflict occurrence, unreported incidents, and subjective safety management evaluations. A statistically significant correlation between patient safety culture and patient safety activities was confirmed in 84.5% of studies. Patient safety culture was the most frequently reported factor influencing patient safety activities. Conclusion Strategies to enhance patient safety culture can promote patient safety activities in South Korean healthcare institutions. Considering organizational and organizational members characteristics when devising these strategies can enhance their effectiveness.

Objectives: The aim of this study was to disseminate information about the safety of bivalent coronavirus disease 2019 (COVID-19) mRNA booster vaccines administered to adults in the Republic of Korea. Methods: Two databases were used to assess the safety of COVID-19 booster doses of Pfizer BA.1, Pfizer BA.4/5, Moderna BA.1, and Moderna BA.4/5 vaccines for adults aged 18 years and older.Adverse events (AEs) were analyzed using data reported to the web-based COVID-19 vaccination management system (CVMS) and a self-reported text-message survey. Results: Between October 11, 2022 and March 30, 2023, the CVMS received reports of 2,369 (93.7%) non-serious AEs from vaccinated adults, along with 158 (6.3%) serious AEs, which included 5 cases of anaphylaxis and 33 deaths. From October 11, 2022 to January 27, 2023, 40,022 people aged 18 and older responded to a survey conducted via text message. The booster doses were associated with fewer local and systemic AEs compared to the original vaccines. After receiving the bivalent vaccine, the most commonly reported AEs were pain at the injection site, headache, fatigue, and myalgia. Conclusion Overall, bivalent vaccines exhibited fewer AEs compared to the original vaccines. The majority of AEs were non-serious, and serious AEs were rare among adults aged 18 years and older following vaccination with the Pfizer and Moderna bivalent vaccines.

Objectives: The aim of this study was to disseminate information about the safety of bivalent coronavirus disease 2019 (COVID-19) mRNA booster vaccines administered to adults in the Republic of Korea. Methods: Two databases were used to assess the safety of COVID-19 booster doses of Pfizer BA.1, Pfizer BA.4/5, Moderna BA.1, and Moderna BA.4/5 vaccines for adults aged 18 years and older.Adverse events (AEs) were analyzed using data reported to the web-based COVID-19 vaccination management system (CVMS) and a self-reported text-message survey. Results: Between October 11, 2022 and March 30, 2023, the CVMS received reports of 2,369 (93.7%) non-serious AEs from vaccinated adults, along with 158 (6.3%) serious AEs, which included 5 cases of anaphylaxis and 33 deaths. From October 11, 2022 to January 27, 2023, 40,022 people aged 18 and older responded to a survey conducted via text message. The booster doses were associated with fewer local and systemic AEs compared to the original vaccines. After receiving the bivalent vaccine, the most commonly reported AEs were pain at the injection site, headache, fatigue, and myalgia. Conclusion Overall, bivalent vaccines exhibited fewer AEs compared to the original vaccines. The majority of AEs were non-serious, and serious AEs were rare among adults aged 18 years and older following vaccination with the Pfizer and Moderna bivalent vaccines.

Objectives: The aim of this study was to disseminate information about the safety of bivalent coronavirus disease 2019 (COVID-19) mRNA booster vaccines administered to adults in the Republic of Korea. Methods: Two databases were used to assess the safety of COVID-19 booster doses of Pfizer BA.1, Pfizer BA.4/5, Moderna BA.1, and Moderna BA.4/5 vaccines for adults aged 18 years and older.Adverse events (AEs) were analyzed using data reported to the web-based COVID-19 vaccination management system (CVMS) and a self-reported text-message survey. Results: Between October 11, 2022 and March 30, 2023, the CVMS received reports of 2,369 (93.7%) non-serious AEs from vaccinated adults, along with 158 (6.3%) serious AEs, which included 5 cases of anaphylaxis and 33 deaths. From October 11, 2022 to January 27, 2023, 40,022 people aged 18 and older responded to a survey conducted via text message. The booster doses were associated with fewer local and systemic AEs compared to the original vaccines. After receiving the bivalent vaccine, the most commonly reported AEs were pain at the injection site, headache, fatigue, and myalgia. Conclusion Overall, bivalent vaccines exhibited fewer AEs compared to the original vaccines. The majority of AEs were non-serious, and serious AEs were rare among adults aged 18 years and older following vaccination with the Pfizer and Moderna bivalent vaccines.

Objectives: The aim of this study was to disseminate information about the safety of bivalent coronavirus disease 2019 (COVID-19) mRNA booster vaccines administered to adults in the Republic of Korea. Methods: Two databases were used to assess the safety of COVID-19 booster doses of Pfizer BA.1, Pfizer BA.4/5, Moderna BA.1, and Moderna BA.4/5 vaccines for adults aged 18 years and older.Adverse events (AEs) were analyzed using data reported to the web-based COVID-19 vaccination management system (CVMS) and a self-reported text-message survey. Results: Between October 11, 2022 and March 30, 2023, the CVMS received reports of 2,369 (93.7%) non-serious AEs from vaccinated adults, along with 158 (6.3%) serious AEs, which included 5 cases of anaphylaxis and 33 deaths. From October 11, 2022 to January 27, 2023, 40,022 people aged 18 and older responded to a survey conducted via text message. The booster doses were associated with fewer local and systemic AEs compared to the original vaccines. After receiving the bivalent vaccine, the most commonly reported AEs were pain at the injection site, headache, fatigue, and myalgia. Conclusion Overall, bivalent vaccines exhibited fewer AEs compared to the original vaccines. The majority of AEs were non-serious, and serious AEs were rare among adults aged 18 years and older following vaccination with the Pfizer and Moderna bivalent vaccines.